Dr Danny Meyersfeld completed his PhD in Molecular Biology in 2005 at University of Witwatersrand, South Africa. Following two years of post-doctoral research, and passionate about the concept of personalised medicine, Danny set up DNAlysis Biotechnology, a company dedicated to the widespread adoption of genomic insights into clinical practice.
Their portfolio of genetic tests has been developed with a focus on scientific integrity and a commitment to ease the transition of complex genetics into medical practices. Receiving widespread acclaim, the tests are now sold in 60 countries with 12 countries having local language reports.
Through their partnership with Nordic Laboratories, they have been responsible for the education, training and support of thousands of clinicians around the world, helping to ensure their panels of genetic tests are used ethically and responsibly for the betterment of patient health outcomes.